Eupraxia Pharmaceuticals (EPRX) FCF Payout Ratio (2023 - 2025)

Eupraxia Pharmaceuticals' (EPRX) quarterly FCF Payout Ratio came in at 15.56 in Q3 2025, down 1177.62% year-on-year from 1.44 in Q3 2024, and down 1749.37% on a QoQ basis from 0.94 in Q2 2025.

Eupraxia Pharmaceuticals (EPRX) FCF Payout Ratio (2023 - 2025) Analysis & Trends

Eupraxia Pharmaceuticals (EPRX) has 3 years of FCF Payout Ratio data on file, last reported at 15.56 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Cover (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 0.12
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Eupraxia Pharmaceuticals 350.77 Mn 350.77 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 -15.56
Jun 30, 2025 0.94
Mar 31, 2025 -4.71
Sep 30, 2024 1.44
Jun 30, 2024 1.64
Mar 31, 2024 -5.86
Sep 30, 2023 -1.71
Jun 30, 2023 -0.12
Mar 31, 2023 -3.05